AYOXXA and Grünenthal collaborate on inflammation markers
AYOXXA Biosystems and Grünenthal have completed their first research collaboration to validate detection limits for a biomarker based on AYOXXA’s platform. The outcomes of this collaboration can be...
View ArticleOxford BioTherapeutics and Invenra to research Cancer-targeting Antibodies
The partnership between Oxford BioTherapeutics and Invenra was only a matter of time. Both biotechs, focused on next-generation therapeutic antibodies will collaborate to identify monoclonal antibodies...
View ArticleStallergenes and Greer to create the World Leader in Allergy Immunotherapy
A few months ago, we were talking about the refusal of Stallergenes’ minority shareholders to merge with Greer laboratories, another competitor within the field of allergy treatment. Finally,...
View ArticleCEVEC and Biotest to ease hemophilia patients’ lifes
A German collaboration seeks to treat the symptoms of hemophilia in patients suffering from the later. CEVEC and Biotest will join forces to produce and commercialize molecules using CEVEC’s expression...
View ArticleMicroalgae on Your Plate Thanks to Algama
Nine billion people will have to be fed by 2050! Amongst the considered solutions, microalgae could be a real game-changer. Algama, a young French startup is in the starting-block, with already two...
View ArticleGreenovation: Using Moss as a Drug Production Factory
Factor H, a key component of the immune system that is missing in patients suffering from atypical hemolytic uremic syndrome (aHUS) was effectively produced in the moss Physcomitrella patens. In...
View ArticleSanofi to solve Growing Resistance against Malarial Treatments
Sanofi extended its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new combination therapy against malaria, the deadliest parasitic disease worldwide. The difficult access...
View ArticleCancer Research Technology grabs Monopar’s Antibody to Beat Cancer
Cancer Research Technology (CRT) expands its portfolio by grabbing the one and only antibody from the emerging company Monopar therapeutics. The experimental antibody treatment will be tested in...
View ArticleProbiodrug bets on basic research with Harvard’s collaboration
Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard...
View ArticleGSK becomes the first Pharma to collaborate with the Francis Crick Institute
The future Francis Crick Institute has established its first industrial collaboration, even before opening its doors. And the lucky nominee couldn’t have been any other than GlaxoSmithKline, the UK’s...
View ArticlePersonalized Cancer medicines are becoming reality thanks to AstraZeneca and...
A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a...
View ArticleFerring bets on bacteriophages to treat inflammatory bowel disease
Bacteriophages have been instinctively killing bacteria for millions of years. These natural bacteria predators represent a potential alternative to antibiotics and Ferring Pharmaceuticals wants to use...
View ArticleHow Servier saved Cellectis, the French CAR-T Miracle
Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months...
View ArticleApogenix heads for the Chinese Market
Apogenix wants to enter the world’s second biggest pharma market. Its lead candidate APG101 was just licensed by CANbridge Life Sciences to treat patients suffering from glioblastomas in China, Macao...
View ArticleNASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy
A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T...
View ArticleCytox and Affymetrix join forces to predict Alzheimer’s disease
Cytox and Affymetrix ally to determine the personal risk of a person to develop Alzheimer’s disease. Hopefully this will do its part to stem the broadening disorder. A forgotten name, not recognizing...
View ArticleRoche exits €940M discovery alliance with Molecular Partners
Roche left the collaboration with Molecular Partners, walking away from a potential cancer treatment using the DARPin technology. The collaboration, entered in 2013, was worth up to €940M. Molecular...
View ArticleAblynx and Merck & Co. (MSD) upgrade their €1.7Bn deal to gigantic €5.7Bn
Using camel antibodies as drugs, sounds crazy? Belgian Ablynx is exactly doing that and has been very successful so far. It’s now moving to the next step. It already signed a €1.7Bn deal with Merck...
View ArticleStruggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M
The Pharma giant AstraZeneca is still struggling even if in better shape. It just sold one of his rare disease drug already on the market to THE rare disease Biotech Genzyme, now part of Sanofi....
View ArticleHow to create a late-stage Biotech company in a record time? Ask Novartis!
Mereo BioPharma. This name doesn’t ring a bell? From now on, you should keep it in mind as it could rapidly become a rising star on the European Biotech scene. Launched five months ago, the company has...
View Article
